Johnson & Johnson (JNJ.DE)
| Previous close | 136.42 |
| Open | 136.04 |
| Bid | 134.30 x 0 |
| Ask | 134.42 x 0 |
| Day's range | 133.90 - 136.20 |
| 52-week range | 132.78 - 161.20 |
| Volume | |
| Avg. volume | 3,713 |
| Market cap | 323.41B |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | 21.47 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.55 (3.33%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | N/A |
- PR Newswire
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
Johnson & Johnson (NYSE:JNJ) announced today positive results from a prespecified second interim analysis of the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) compared to standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) for the treatment of patients with relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy. The interim analysis showed a statistically
- PR Newswire
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
Johnson & Johnson (NYSE: JNJ) today announced positive results from the nipocalimab Phase 3 Vivacity-MG3 study in patients with generalized myasthenia gravis (gMG). Patients treated with nipocalimab plus standard of care (SOC) achieved superiority over placebo plus SOC as measured by the primary endpoint of improvement in the MG-ADL score from baseline over 24 weeks. These data are included in a presentation and are among eight abstracts that Johnson & Johnson will present at the European Academ
- Business Wire
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
NEW BRUNSWICK, N.J., June 21, 2024--Johnson & Johnson (NYSE: JNJ) announced today that it has successfully completed the acquisition of Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash with potential for an additional milestone payment, as announced on May 16, 2024.
